Valuation: Roche Holding AG

Market Cap 268B 333B 291B 248B 470B 31,713B 478B 3,205B 1,259B 15,623B 1,248B 1,221B 53,709B P/E 2026 *
18x
P/E 2027 * 16.7x
Enterprise Value 279B 346B 302B 258B 489B 32,961B 497B 3,332B 1,308B 16,238B 1,298B 1,269B 55,822B EV / Sales 2026 *
4.45x
EV / Sales 2027 * 4.17x
Free-Float
88.78%
Yield 2026 *
2.97%
Yield 2027 * 3.05%
1 day-1.35%
Current month+3.91%
6 months-1.33%
Current year+2.04%
Current year 315.6
Extreme 315.6
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 333B
-2.33%-2.09%+49.88%+169.76% 1,060B
-0.82%-2.30%+63.79%+62.56% 619B
-0.73%-4.98%+28.91%+83.79% 438B
-0.02%-2.85%+29.15%+46.14% 282B
-3.89%-11.22%+22.81%+25.23% 267B
+0.66%-1.42%-26.59%-37.67% 218B
-0.06%-2.88%+23.07%+61.02% 196B
-3.72%-1.10%+18.41%+69.98% 161B
-0.33%-0.62%-5.77%-32.84% 138B
Average -1.26%-3.27%+22.63%+49.78% 375.46B
Weighted average by Cap. -1.43%-3.18%+35.57%+84.52%

Financials

2026 *2027 *
Net sales 62.64B 77.65B 67.92B 57.86B 110B 7,405B 112B 748B 294B 3,648B 292B 285B 12,541B 65.28B 80.91B 70.77B 60.29B 114B 7,716B 116B 780B 306B 3,801B 304B 297B 13,068B
Net income 15.22B 18.86B 16.5B 14.05B 26.67B 1,799B 27.12B 182B 71.4B 886B 70.82B 69.28B 3,046B 16.32B 20.23B 17.69B 15.07B 28.6B 1,929B 29.08B 195B 76.57B 950B 75.94B 74.29B 3,267B
Net Debt 10.56B 13.08B 11.44B 9.75B 18.5B 1,248B 18.81B 126B 49.53B 615B 49.13B 48.06B 2,113B 3.92B 4.86B 4.25B 3.62B 6.87B 463B 6.98B 46.82B 18.39B 228B 18.24B 17.84B 785B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA